Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

81. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials using a direct oral anticoagulant

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials using a direct oral anticoagulant Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2019 PROSPERO

82. Anticoagulant agents for preventing thromboembolic events in patients with atrial fibrillation and chronic kidney disease 3-5D stage: a systematic review

Anticoagulant agents for preventing thromboembolic events in patients with atrial fibrillation and chronic kidney disease 3-5D stage: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

83. Assessment of sex-related quality of oral anticoagulation control: systematic review

Assessment of sex-related quality of oral anticoagulation control: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

84. Comparative efficacy of anticoagulant versus antiplatelet therapy for stroke prevention in patients with embolic stroke of undetermined source (ESUS): a systematic review and meta-analysis of randomized controlled trials

Comparative efficacy of anticoagulant versus antiplatelet therapy for stroke prevention in patients with embolic stroke of undetermined source (ESUS): a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate

2019 PROSPERO

85. A systematic review of economic evaluations of service models to increase anticoagulation prescription rates for people with atrial fibrillation

A systematic review of economic evaluations of service models to increase anticoagulation prescription rates for people with atrial fibrillation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

86. Efficacy and safety of Xa inhibitors in patients with heart failure but without long-term anticoagulation: a meta-analysis of randomized controlled trials

Efficacy and safety of Xa inhibitors in patients with heart failure but without long-term anticoagulation: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

87. Direct oral anticoagulation versus warfarin for postoperative atrial fibrillation following cardiac surgery: a systematic review and meta-analysis

Direct oral anticoagulation versus warfarin for postoperative atrial fibrillation following cardiac surgery: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

88. Direct effectiveness and safety comparison of direct-acting oral anticoagulants (DOACs): a systematic review and meta-analysis of real world studies

Direct effectiveness and safety comparison of direct-acting oral anticoagulants (DOACs): a systematic review and meta-analysis of real world studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

89. Instruments for the assessment of patient adherence to oral anticoagulation with warfarin: systematic review

Instruments for the assessment of patient adherence to oral anticoagulation with warfarin: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

90. Factors influencing oral anticoagulant prescribing decisions for patients with atrial fibrillation: a systematic review of qualitative and quantitative evidence

Factors influencing oral anticoagulant prescribing decisions for patients with atrial fibrillation: a systematic review of qualitative and quantitative evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

91. Anticoagulation - oral

Anticoagulation - oral Anticoagulation - oral - NICE CKS Share Anticoagulation - oral: Summary There are five oral anticoagulants licensed for use in the UK: warfarin, apixaban, dabigatran, edoxaban and rivaroxaban. Apixaban, dabigatran, edoxaban and rivaroxaban are newer anticoagulants which may be prescribed instead of warfarin for people with non-valvular atrial fibrillation (NVAF): Apixaban, dabigatran, edoxaban and rivaroxaban have been approved by the National Institute for Health (...) , regular follow up and monitoring is still required to: Assess compliance. Enquire about the presence of any adverse effect (e.g. bleeding). Assess for the presence of thromboembolic events (e.g. symptoms of stroke, or breathlessness which may suggest a pulmonary embolism). The most common adverse effect of anticoagulants is bleeding; however, while there is an antidote for warfarin, of the new anticoagulants, there is currently only an antidote for dabigatran. Management of a bleeding complication

2019 NICE Clinical Knowledge Summaries

92. Non-vitamin K antagonist oral anticoagulants for cancer associated thrombosis: are there differences between real-world practice and trials? A critical systematic review and meta-analysis

Non-vitamin K antagonist oral anticoagulants for cancer associated thrombosis: are there differences between real-world practice and trials? A critical systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

93. What is the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an ACS and a separate indication for anticoagulation?

What is the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an ACS and a separate indication for anticoagulation? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

94. The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews

The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews anticoagulation medicines 18 March 2019 Links Download reports (pdf) Evidence Summary Evidence Report The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews. What do we want to know? Anticoagulation drugs are used to prevent and treat irregular heartbeat (atrial fibrillation, AF), and clotting of blood in veins (venous thromboembolism, VTE (...) ). Until recently, warfarin was the only available drug to manage or prevent these conditions. Recently, novel oral anticoagulants (NOACs) have become available for prescription. To bring together current understanding about these treatments, we sought to address broad research questions: What evidence syntheses have been conducted to address the efficacy and safety of UK-approved oral anticoagulant therapy with respect to warfarin, novel oral anticoagulants, genotyping (i.e. using genetic information

2019 EPPI Centre

95. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta-analysis, we aimed to assess outcomes with reduced-dose NOACs when given as pre-specified in pivotal trials.Aggregated data abstracted from Phase III trials (...) , fatal bleeding, and death regardless of patient eligibility for NOAC dose reduction (interaction P > 0.05 for each).Patients eligible for reduced-dose NOACs were at elevated risk of thromboembolic and haemorrhagic complications when treated with anticoagulants. NOACs, when appropriately dose-adjusted, had an improved benefit-harm profile compared with warfarin. Our findings highlight the importance of prescribing reduced-dose NOACs for indicated patient populations.

Full Text available with Trip Pro

2019 EvidenceUpdates

96. Oral anticoagulant versus antiplatelet treatment in patients with ischemic stroke and supracardiac atherosclerosis: a systematic review and meta-analysis of randomized controlled trials

Oral anticoagulant versus antiplatelet treatment in patients with ischemic stroke and supracardiac atherosclerosis: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

97. Safety and efficacy of anticoagulant treatment in splanchnic vein thrombosis: a systematic review

Safety and efficacy of anticoagulant treatment in splanchnic vein thrombosis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

98. The efficacy and safety of direct oral anticoagulants for the prevention of cardiovascular events in patients with clinical cardiovascular disease: a systematic review and meta-analysis of randomized clinical trials

The efficacy and safety of direct oral anticoagulants for the prevention of cardiovascular events in patients with clinical cardiovascular disease: a systematic review and meta-analysis of randomized clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete

2019 PROSPERO

99. Efficacy and safety of new oral anticoagulants on patients undergoing arthroplasty: a meta-analysis of randomized controlled trials

Efficacy and safety of new oral anticoagulants on patients undergoing arthroplasty: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

100. Comparative efficacy and safety of new oral anticoagulants versus classic therapies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis

Comparative efficacy and safety of new oral anticoagulants versus classic therapies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO